Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$804.90 +0.7%	$717.49	$510.05 ▼ $808.43	$48.90B	0.46	351,908 shs	222,954 shs
GSK GSK	$43.42 +0.2%	$40.21	$31.72 ▼ $45.59	$88.19B	0.53	5.75 million shs	4.43 million shs
TAK Takeda Pharmaceutical	$14.10 -1.5%	$14.87	$12.80 ▼ $15.69	$45.53B	0.21	2.54 million shs	2.33 million shs
TEVA Teva Pharmaceutical Industries	$20.05 -0.8%	$18.42	$12.47 ▼ $22.80	$23.18B	0.71	10.59 million shs	9.87 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+0.75%	+1.68%	+4.94%	+43.67%	+54.63%
GSK GSK	+0.14%	-0.55%	+6.21%	+13.40%	+7.90%
TAK Takeda Pharmaceutical	-1.54%	-2.25%	-7.72%	-3.89%	-1.23%
TEVA Teva Pharmaceutical Industries	-0.84%	+0.00%	+1.83%	+22.33%	+13.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$804.90 +0.7%	$717.49	$510.05 ▼ $808.43	$48.90B	0.46	351,908 shs	222,954 shs
GSK GSK	$43.42 +0.2%	$40.21	$31.72 ▼ $45.59	$88.19B	0.53	5.75 million shs	4.43 million shs
TAK Takeda Pharmaceutical	$14.10 -1.5%	$14.87	$12.80 ▼ $15.69	$45.53B	0.21	2.54 million shs	2.33 million shs
TEVA Teva Pharmaceutical Industries	$20.05 -0.8%	$18.42	$12.47 ▼ $22.80	$23.18B	0.71	10.59 million shs	9.87 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+0.75%	+1.68%	+4.94%	+43.67%	+54.63%
GSK GSK	+0.14%	-0.55%	+6.21%	+13.40%	+7.90%
TAK Takeda Pharmaceutical	-1.54%	-2.25%	-7.72%	-3.89%	-1.23%
TEVA Teva Pharmaceutical Industries	-0.84%	+0.00%	+1.83%	+22.33%	+13.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	3.00	Buy	$813.32	1.05% Upside
GSK GSK	1.88	Reduce	$37.38	-13.92% Downside
TAK Takeda Pharmaceutical	2.00	Hold	N/A	N/A
TEVA Teva Pharmaceutical Industries	3.00	Buy	$25.57	27.54% Upside

Current Analyst Ratings Breakdown

Latest TEVA, GSK, ARGX, and TAK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2025	ARGX argenex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
10/8/2025	GSK GSK	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
10/8/2025	TEVA Teva Pharmaceutical Industries	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/3/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$23.00 ➝ $26.00
10/1/2025	ARGX argenex	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$766.00 ➝ $1,040.00
9/27/2025	ARGX argenex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
9/27/2025	GSK GSK	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
9/27/2025	TAK Takeda Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
9/27/2025	TEVA Teva Pharmaceutical Industries	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/24/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$23.00 ➝ $26.00
9/22/2025	ARGX argenex	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$3.05B	16.14	$2.99 per share	268.96	$90.49 per share	8.89
GSK GSK	$31.63B	2.79	$5.59 per share	7.77	$8.07 per share	5.38
TAK Takeda Pharmaceutical	$30.09B	1.49	$3.13 per share	4.50	$14.39 per share	0.98
TEVA Teva Pharmaceutical Industries	$16.54B	1.39	$3.34 per share	6.01	$4.74 per share	4.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$833.04M	$19.50	41.28	74.18	0.87	40.98%	21.06%	18.25%	10/30/2025 (Estimated)
GSK GSK	$3.29B	$2.16	20.10	9.34	1.95	10.81%	49.22%	11.31%	10/29/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.30	47.00	8.55	N/A	3.20%	10.50%	5.10%	10/30/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$0.16	N/A	7.62	1.17	-0.95%	46.10%	7.18%	11/5/2025 (Estimated)

Latest TEVA, GSK, ARGX, and TAK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2025	Q3 2025	TEVA Teva Pharmaceutical Industries	$0.68	N/A	N/A	N/A	$4.36 billion	N/A
10/30/2025	Q3 2025	ARGX argenex	$4.34	N/A	N/A	N/A	$909.86 million	N/A
10/30/2025	Q2 2026	TAK Takeda Pharmaceutical	$0.46	N/A	N/A	N/A	$8.01 billion	N/A
10/29/2025	Q3 2025	GSK GSK	$1.22	N/A	N/A	N/A	$8.21 billion	N/A
7/31/2025	Q2 2025	ARGX argenex	$2.84	$3.74	+$0.90	$3.74	$776.82 million	$866.79 million
7/30/2025	Q2 2025	GSK GSK	$1.12	$1.23	+$0.11	$0.94	$7.92 billion	$10.64 billion
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	$0.52	+$0.05	$0.27	$7.96 billion	$7.45 billion
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	$0.66	+$0.02	$0.24	$4.34 billion	$4.18 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
GSK GSK	$1.68	3.87%	N/A	77.78%	N/A
TAK Takeda Pharmaceutical	$0.55	3.90%	N/A	183.33%	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Latest TEVA, GSK, ARGX, and TAK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
1/1/2100	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.60	5.27
GSK GSK	1.07	0.87	0.57
TAK Takeda Pharmaceutical	0.60	1.16	0.59
TEVA Teva Pharmaceutical Industries	2.45	1.06	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
GSK GSK	15.74%
TAK Takeda Pharmaceutical	9.17%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
GSK GSK	10.00%
TAK Takeda Pharmaceutical	0.04%
TEVA Teva Pharmaceutical Industries	0.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,599	61.20 million	59.71 million	Optionable
GSK GSK	68,629	2.03 billion	1.83 billion	Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

TEVA, GSK, ARGX, and TAK Headlines

Recent News About These Companies

Vontobel Holding Ltd. Has $12.06 Million Stake in Teva Pharmaceutical Industries Ltd. $TEVA

1 hour ago | marketbeat.com

Zacks Research Has Positive Forecast for TEVA Q3 Earnings

3 hours ago | americanbankingnews.com

Teva Pharmaceutical Industries (NYSE:TEVA) Receives "Sell (D-)" Rating from Weiss Ratings

October 9 at 7:48 PM | marketbeat.com

Zacks Research Issues Positive Forecast for TEVA Earnings

October 8 at 8:13 AM | marketbeat.com

DAVENPORT & Co LLC Decreases Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

October 8 at 4:16 AM | marketbeat.com

Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside

October 7 at 5:01 AM | seekingalpha.com

Billionaire Stanley Druckenmiller Sold His Fund's Stakes in Nvidia and Palantir, and Has Piled Into These 2 Phenomenal Stocks for 4 Straight Quarters

October 6, 2025 | fool.com

Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Public Employees Retirement System of Ohio

October 5, 2025 | marketbeat.com

JPMorgan Chase & Co. Issues Positive Forecast for Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price

October 5, 2025 | americanbankingnews.com

JP Morgan Maintains Teva Pharmaceutical Industries Limited - Depositary Receipt (TEVA) Overweight Recommendation

October 4, 2025 | msn.com

Truist Financial Corp Reduces Stake in Teva Pharmaceutical Industries Ltd. $TEVA

October 4, 2025 | marketbeat.com

Teva (TEVA) Is Up 9.2% After New Schizophrenia Drug Data and Innovation Shift - What’s Changed

October 3, 2025 | finance.yahoo.com

Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $26.00

October 3, 2025 | marketbeat.com

Greenwood Capital Associates LLC Decreases Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

October 3, 2025 | marketbeat.com

UBS Maintains its Buy Rating on Teva Pharmaceutical Industries Limited (TEVA); Raises Its Price Target to $26.00

October 1, 2025 | insidermonkey.com

Truist Securities Reaffirms Its Buy Rating for Teva Pharmaceutical Industries Limited (TEVA)

October 1, 2025 | insidermonkey.com

Teva Pharmaceutical Industries Target of Unusually High Options Trading (NYSE:TEVA)

September 30, 2025 | marketbeat.com

Unpacking the Latest Options Trading Trends in Teva Pharmaceutical Indus

September 30, 2025 | benzinga.com

Teva Pharmaceutical Industries (NYSE:TEVA) Trading Up 4.3% - Should You Buy?

September 30, 2025 | marketbeat.com

Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

September 30, 2025 | zacks.com

Bourgeon Capital Management LLC Acquires 363,252 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

September 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TEVA, GSK, ARGX, and TAK Company Descriptions

argenex NASDAQ:ARGX

$804.90 +5.96 (+0.75%)

Closing price 10/9/2025 04:00 PM Eastern

Extended Trading

$802.92 -1.98 (-0.25%)

As of 04:07 AM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

GSK NYSE:GSK

$43.42 +0.07 (+0.16%)

Closing price 10/9/2025 03:59 PM Eastern

Extended Trading

$43.82 +0.40 (+0.92%)

As of 04:53 AM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Takeda Pharmaceutical NYSE:TAK

$14.10 -0.21 (-1.47%)

Closing price 10/9/2025 03:59 PM Eastern

Extended Trading

$13.81 -0.29 (-2.06%)

As of 04:48 AM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Teva Pharmaceutical Industries NYSE:TEVA

$20.05 -0.16 (-0.79%)

Closing price 10/9/2025 03:59 PM Eastern

Extended Trading

$20.08 +0.04 (+0.17%)

As of 04:53 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TEVA, GSK, ARGX, and TAK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TEVA, GSK, ARGX, and TAK Earnings

Compare Dividends

Latest TEVA, GSK, ARGX, and TAK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TEVA, GSK, ARGX, and TAK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TEVA, GSK, ARGX, and TAK Company Descriptions

argenex NASDAQ:ARGX

GSK NYSE:GSK

Takeda Pharmaceutical NYSE:TAK

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TEVA, GSK, ARGX, and TAK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TEVA, GSK, ARGX, and TAK Earnings

Compare Dividends

Latest TEVA, GSK, ARGX, and TAK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TEVA, GSK, ARGX, and TAK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TEVA, GSK, ARGX, and TAK Company Descriptions

argenex NASDAQ:ARGX

GSK NYSE:GSK

Takeda Pharmaceutical NYSE:TAK

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools